Strategies to achieve personalized medicine and improve
public health encompass assessment of an individual's risk for disease, early detection, and molecular classification of disease resulting in an informed choice of the most appropriate treatment instituted at an early stage of disease development. An unmet need in this field for which proteomics is well suited to make a major contribution is the development of blood-based tests for early cancer detection. This is illustrated in proteomic studies of epithelial cancer that encompass analysis of specimens collected both at the time of diagnosis and specimens collected before onset of symptoms that are particularly suited for the identification of early detection markers. This overarching effort benefits from the availability of plasmas from subject cohorts and of engineered mouse models that are sampled at early stages of tumor development. Integration of findings from plasma with tumor tissue and cancer cell proteomic and genomic data allows elucidation of signatures in plasma for altered signaling pathways. The discovery and further development of early detection markers take advantage of the availability of in-depth quantitative proteomics methods and bioinformatics resources for data mining. W hile the concept of blood-based cancer tests is simple, the development of such tests has been challenging, to the point that very few cancer-related biomarker assays have been approved by the US Food and Drug Administration in recent years. The development of biomarker panels for early cancer detection is particularly challenging given the need for sensitivity and specificity tests at a time when tumors are in early development. The difficulty in identifying markers with suitable performance for early detection is illustrated in the recent findings from an ovarian cancer protein marker validation study. 1Y3 Numerous studies in hundreds of publications have reported the identification of protein biomarker candidates that showed promise for the early detection of ovarian cancer. To further assess the performance of candidate markers, a recent validation study encompassed 28 ovarian cancer protein candidates that were selected for assay in prediagnostic serum specimens from ovarian cancer cases and controls from the Prostate, Lung, Colorectal, and Ovarian Cancer screening trial. None of the individual markers exhibited performance characteristics that matched those of CA125Vthe current best marker for ovarian cancer. Even when biomarkers were combined into panels based on predefined models, there was little improvement in performance compared with CA125 alone. In another study of proteomic biomarker candidates together with CA125, a sensitivity of 84% at a specificity of 98% was observed in an analysis of sera from patients who had stage I disease at the time of surgery relative to controls, which was significantly better than CA125 alone, leading to a validation study in prediagnostic sera from the Prostate, Lung, Colorectal, and Ovarian Cancer trial. The findings also from this study indicated that the panel did not augment the performance of CA125 alone. 4 The negative results observed in these validation studies highlight the challenges involved in the development biomarkers with sufficient performance to be suitable for early cancer detection. They have engendered a negative outlook on biomarkers 5 necessitating a reassessment of strategies to discover and develop cancer biomarkers. Such reassessment is relevant not only to protein biomarkers but also more broadly to various types of markers.
Here we present strategies for finding proteins biomarkers and emphasize the need for rigor in experimental design, the critical importance of the choice of biospecimens for analysis and the need to apply technologies with the prerequisite sensitivity and quantitative accuracy to identify and quantify low abundance proteins that signal the presence of cancer at an early stage. We present findings from the application of these strategies to solid tumors and, in particular, to lung cancer.
THE NEED FOR BLOOD BASED TESTS TO DETECT CANCER
The rich content of blood in thousands of proteins that have the potential to inform about the health status of an individual provides an ideal compartment to develop noninvasive diagnostics for cancer. Protein markers currently in clinical use, which include CA125 for ovarian cancer, CA19-9 for pancreatic cancer, carcinoembryonic antigen for colon cancer, and prostate-specific antigen for prostate cancer, have limited utility for cancer detection. 6 Other common cancers notably breast and lung lack established blood-based biomarkers with demonstrated clinical utility in a screening setting. Imaging modalities have utility for detecting cancer early. However, they have substantial limitations. In the case of colorectal cancer (CRC), while current screening methods have affected mortality associated with this disease, 7 it is estimated that È60% of subjects older than 50 years in the United States are not screened at recommended intervals. 8, 9 Even when subjects are referred by their physician for colonoscopy, there is only a È50% rate of adherence. 10 In the case of lung cancer, imaging-based screening to detect lung cancer has shown promise as demonstrated in a recently completed National Cancer InstituteYinitiated national lung screening. 11 However, the thin slices provided by multidetector row scanners have led to the detection of large numbers of small pulmonary nodules that turn out not to be nonmalignant. The frequency of detecting noncalcified nodules on a single computerized tomographic varies from 5% to 60% in a lung cancer screening population. 12, 13 Given the high probability of false-positive findings associated with computerized tomographic screening for lung cancer, there is a substantial need for additional modalities to complement imaging. Blood-based biomarkers provide for simple noninvasive tests for screening as well as disease classification and monitoring for cancer progression and regression. types as exemplified for lung cancer. 15, 16 In 1 recent study, circulating levels of 47 biomarkers were evaluated against patient cohorts consisting of 90 nonYsmall cell lung cancer (NSCLC) and 43 high-risk controls using immunoassays. 17 Multivariate statistical methods then identified a panel of 6 biomarkers (tumor necrosis factor >, CYFRA 21-1, interleukin-1ra, matrix metalloproteinase 2, monocyte chemotactic protein 1, and sE-selectin) as being the most efficacious for diagnosing early-stage NSCLC. These markers were tested as a panel against a second patient cohort with correct classification of 75 of 88 patients tested, pointing to the potential of novel markers to contribute to the development of a panel that has utility for early detection. While currently a large number of candidate markers have been reported in the literature that may have utility for cancer early detection, critical validation studies of utility based on prospective cohorts have been either lacking or have largely been negative as presented for ovarian cancer.
In contrast with studies that were based on a small number of preselected candidates for discovery of cancer markers, proteomics allows an unbiased comprehensive search for biomarkers in biospecimens. The development of mass spectrometry for protein identification, in particular electrospray ionization 14 coupled with various prefractionation and separation schemes and protein labeling, has allowed quantitative analysis of an ever-increasing number of proteins from cells, tissues and biological fluids ( Fig. 1) . As a result, the identification of a protein product for virtually all expressed genes in a cancer cell population has become achievable. Likewise, nearly exhaustive identification of proteins associated with particular cell compartments such as proteins expressed on the cell surface or are secreted or otherwise released into the extracellular space, as well as proteins with particular posttranslational modifications, is currently feasible. 18Y21 Also for plasma and other biological fluids, mass spectrometry has sufficiently advanced to allow quantitative proteome profiling across no less than 7 logs of protein abundance. 22 In parallel with developments in the field of mass spectrometry for proteomics, microarray-based strategies with spotted affinity capture agents have provided a complementary approach to interrogate proteomes. 23 These technologies have been applied to tissues, biological fluids, and cell populations to identify potential cancer markers.
Illustrative of the diversity in the type of specimens used for biomarker discovery is a strategy for lung cancer biomarker discovery based on comparative proteomic profiling of pulmonary venous effluent draining the tumor vascular bed and of systemic arterial blood obtained from the same subjects. The concept is that effluent blood contains higher concentrations of potential biomarkers compared with more distal blood. A candidate biomarker (NAP-2/CXCL7) was identified that potentially has utility for detecting lung cancer up to 30 months before clinical diagnosis. 24 Posttranslational modifications, notably glycosylation, are an important source of cancer biomarkers. 25 Strategies to identify glycosylated proteins associated with cancer have involved both mass spectrometry and microarray based methodology and strategies for integrating proteomics and glycomics are under development. 26 An antibodyYlectin sandwich array method was used to characterize both the protein and glycan levels of specific mucins and carcinoembryonic antigenYrelated proteins from the sera of pancreatic cancer patients and control subjects. 27 MUC1 and MUC5AC proteins showed highly prevalent and distinct glycan alterations between cases and controls. The most significant elevation was the CA19-9 on MUC1 among cases relative to controls. A comparison of glycoproteins isolated from the serum of healthy subjects with those from patients with lung adenocarcinoma using multilectin affinity chromatography uncovered a large number of cancer-selective proteins, which included kallikrein N plasma 1 (KLKB1) and interY>-trypsin inhibitor heavy chain 3 (ITIH3). 28 In another study, a glycoprotein analysis approach was undertaken using high-resolution Fourier transform ion cyclotron resonance mass spectrometry to analyze glycosylated proteins present in sera obtained from ovarian cancer patients and healthy controls. 29 Some of the glycoproteins analyzed exhibited N-linked glycan fragments in forms that were distinct from the glycans obtained from the corresponding proteins in serum from healthy controls.
INNOVATIVE CONCEPTS IN THE APPLICATION OF PROTEOMICS FOR THE DISCOVERY OF EARLY DETECTION MARKERS

Mouse to Human Strategies for the Discovery of Circulating Protein Biomarkers
An approach to overcome the complexity and heterogeneity of the human plasma proteome that represent important challenges toward the identification of protein changes associated with tumor development relies on the use of refined genetically engineered mouse models of human cancer that faithfully recapitulate the molecular, biological, and clinical features of human disease. The merits of well-characterized GEM models have been exploited in several studies aimed at identifying protein biomarkers in cancer. Plasma from a GEM model of pancreatic cancer was sampled from mice at early and advanced stages of tumor development and from matched controls. 30 Using a proteomic approach based on extensive protein fractionation, 1442 proteins that were distrib-uted across 7 orders of magnitude of abundance in plasma were identified. Analysis of proteins chosen on the basis of increased levels in plasma from tumor-bearing mice and corroborating protein or RNA expression in tissue documented concordance in the blood from newly diagnosed subjects with pancreatic cancer compared with controls. A panel of 5 proteins was selected on the basis of their increased level at an early stage of tumor development in the mouse discriminated in a blinded study of prediagnostic pancreatic cancer sera obtained before onset of symptoms from matched controls from the same cohort. In another study of lung cancer, plasma protein profiles of 4 mouse models of lung cancer were compared with profiles of models of pancreatic, ovarian, colon, prostate, and breast cancer and 2 models of inflammation (Fig. 2) . 31 A protein signature for Titf1/Nkx2-1, a known lineage survival oncogene in lung cancer, was found in plasmas of mouse models of lung adenocarcinoma. An epidermal growth factor receptor (EGFR) signature was found in the plasma of an EGFR mutant model, and a distinct plasma signature related to neuroendocrine development was uncovered in the small cell lung cancer model. The relevance to human lung cancer of the protein signatures identified based on mouse models was demonstrated based on assays of a subset of markers in plasmas FIGURE 1. In-depth quantitative analysis by means of liquid chromatographyYmass spectrometry of proteins in a pair of plasmas from a cancer case and a control. Plasmas from case and from control are subjected to isotopic labeling of proteins followed by pooling and fractionation of the pool before mass spectrometry analysis of digested fraction. Columns represent individual fractions; rows represent individual proteins identified in particular fractions. The color scheme is indicative of case-to-control concentrations ratios (red = increased, yellow = no change, and green = decreased) for individual proteins based on differential isotope labeling. The ratio for an individual protein is determined based on the isotopic envelopes of case and control for a given peptide as shown for an EGFR peptide. obtained at the time of diagnosis of lung cancer as well as in prediagnostic plasmas. Given the availability of a large number of mouse models of cancer driven by manipulation of oncogenes and tumor suppressor genes relevant to the human counterparts, approaches to the discovery of biomarkers using such models are likely to be highly beneficial.
Immune Response to Tumor Antigens as a Source of Biomarkers
An immune response to tumor antigens occurs early during tumor development and engenders an amplified signal detectable in the blood in the form of autoantibodies. There are numerous reports describing the identification of autoantibodies in sera of newly diagnosed subjects with solid tumors based on a multitude of technologies. 32 A breast cancer study aimed at developing multiautoantibody panels that could aid diagnosis tested a set of 7 antigens (p53, c-myc, HER2, NY-ESO-1, BRCA1, BRCA2, and MUC1) using sera from 97 patients with breast cancer, 40 with ductal carcinoma in situ, and 94 healthy controls. A panel consisting of 6 of the 7 antigens achieved 64% sensitivity with 85% specificity for invasive breast cancer, while the sensitivity of individual autoantibodies ranged from 8% to 34%. 26, 33 In ano-ther recent study, 5 clones from a phage complementary DNA expression library were subjected to blinded validation in a set of sera from patients with early CRC and controls. 34 The classifier yielded high discrimination between cases and controls including among CRC subjects with low serum levels of carcinoembryonic antigen. A limitation of the classifier stems from its failure to distinguish between CRC patients and subjects with autoimmune disease.
Proteomic approaches have relied in part on interrogation of microarrays spotted with recombinant or with natural tumor derived proteins to identify novel antigens. Such a protein microarray approach was applied to discover novel lung cancer tumor antigens and to successfully validate the performance of a set of antigens previously found to be associated with autoantibodies in sera collected at the time of diagnosis of lung cancer. 35Y37 A blinded validation study using prediagnostic sera from the A-Carotene and Retinol Efficacy Trial (CARET) cohort was done to determine whether annexin I, PGP9.5, 14-3-3 theta antigens, and LAMR1 previously found to be targets of autoantibodies in newly diagnosed subjects with lung cancer are associated with autoantibodies in sera collected at the presymptomatic stage. 38 Individual sera collected from 85 subjects within a year before a FIGURE 2. A mouse-to-human search for lung cancer plasma protein markers. Unsupervised hierarchical clustering of plasma proteome profile of mouse models of cancer resulted in clustering of proteomes from lung adenocarcinomas and small cell lung cancer. Validation studies of a panel of candidate markers (EGFR, SFTPB, WFDC2, and ANGPTL3) identified in mouse models of lung adenocarcinoma yielded a significant area under the curve (AUC) for the individual markers and the combined panel in plasmas from newly diagnosed subjects with lung cancer and in prediagnostic plasmas relative to controls. Likewise, a validation study of ROBO1, a candidate marker identified in plasma from the small cell lung cancer mouse model, resulted in significantly increase levels in plasmas from subjects with small cell lung cancer relative to controls. diagnosis of lung cancer and 85 matched controls were assayed. Statistically significant reactivity was observed among cases relative to controls for autoantibodies tested with a similar frequency of reactivity in prediagnostic specimens as previously observed with samples from newly diagnosed subjects. An elegant proteomic approach for identifying tumor antigens consists of mass spectrometry analysis of peptides bound to soluble human leukocyte antigen molecules (sHLA). 39 Immunoaffinity purification of the sHLA molecules from plasma of multiple myeloma and leukemia patients and controls identified thousands of sHLA peptides, including some cancer-related peptides, present among the sHLA peptidomes of the cancer patients.
Discovery Studies of Early Detection Markers Based on Analysis of Prediagnostic Specimens
Most studies aimed at identifying markers potentially applicable for early cancer detection are based on specimens obtained at the time of cancer diagnosis. The molecular features and protein constituents of such specimens may not be particularly relevant to the detection of cancer at the earliest stages. The use of specimens collected at earlier time points through cohort studies has been widely implemented for risk marker studies. 40Y42 An indepth quantitative proteomic analysis of plasma comparing samples collected from estrogen receptorYpositive breast cancer patients who were collected up to 17 months before diagnosis and from matched controls led to the identification of EGFR as a potential predictor of breast cancer risk, leading to a validation study in an independent set of preclinical plasma samples yielding an odds ratio (OR) of 1.44 (P = 0.0008) for women overall and an OR of 2.49 (P = 0.0001) for current users of estrogen plus progestin menopausal hormone therapy. 43 Thus, the use of specimens collected at earlier time points through cohort studies for the discovery of early detection markers is feasible and may be more representative of the screening setting for early cancer detection.
BEYOND TECHNOLOGY: THE NEED FOR A ROAD MAP TO DEVELOP PROTEIN BIOMARKERS FOR EARLY DETECTION
Most serum and plasma biomarker studies have involved analysis of a relatively small number of samples obtained at a single institution. The challenge for the next decade will be to bring discoveries to the clinic in ways that are efficient and practical. Such an objective requires a collaborative effort that brings together scientific teams with expertise in proteomics and in various aspects of biomarker research from discovery to validation of clinical utility. Critical to this effort is the need to address some key requirements including the following:
1. Adequate representation of disease heterogeneity in the discovery process 2. Adequate attention to reducing sources of bias in biospecimens subjected to analysis that result in false discovery due to confounding conditions 3. Implementation of discovery and validation studies that rely on samples that are most relevant to the intended clinical application 44 and that represent independent sets 4. Reliance on technologies that provide sufficient depth of analysis and quantitative accuracy and reproducibility 5. Integration of biomarker data from multiple independent sources 6. Implementation of a plan that envisions proceeding from discovery through various phases of validation toward the intended clinical application
